US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028

2.1 Classification of Transdermal Patches
2.2 Why There Exist Need for Transdermal Patches?
2.3 Mechanism of Transdermal Patch Drug Delivery

3.1 Current Market Scenario
3.2 Patch Market Opportunity Assessment By Indication
3.2.1 Parkinson’s Disease
3.2.2 Alzheimer's Disease
3.2.3 Female Contraceptive
3.2.4 Nicotine Replacement Therapy
3.2.5 Cardiovascular Disease
3.2.6 Insulin
3.2.7 Vaccine
3.3 US Transdermal Patch Market Future Trends

4.1 By Company
4.2 By Drug Class
4.3 By Indication
4.4 By Phase

5.1 Clonidine Transdermal Patch (Catapres-TTS)
5.2 Nitroglycerin Transdermal Patch

6.1 Fentanyl Transdermal Patch (Duragesic)
6.2 Buprenorphine Transdermal Patch (Butrans Patch)

7.1 Selegiline Transdermal Patch (Emsam)
7.2 Scopolamine Transdermal Patch (Transderm-Scop)
7.3 Rivastigmine Transdermal Patch (Exelon)
7.4 Methylphenidate Transdermal Patch (Daytrana)
7.5 Asenapine Transdermal Patch (Secuado)
7.6 Rotigotine Transdermal Patch (Neupro)
7.7 Donepezil Transdermal Patch (Adlarity)
7.8 Dextroamphetamine Transdermal Patch (Xelstrym)

8.1 Estradiol Transdermal Patch
8.2 Testosterone Transdermal Patch (Androderm)
8.3 Ethinyl Estradiol & Norelgestromin Transdermal Patch
8.4 Estradiol/Levonorgestrel Transdermal Patch (Climara Pro)
8.5 Ethinyl Estradiol/Levonorgestrel (Twirla)

9.1 Nicotine Transdermal Patch (Nicoderm CQ/Harbitrol)
9.2 Oxybutynin Transdermal Patch (Oxytrol)
9.3 Sancuso (Granisetron)

10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III
10.7 Preregistration
10.8 Registered

12.1 Favorable Market Parameters
12.2 Commercialization Challenges

13.1 AbbVie
13.2 Amneal Pharmaceuticals
13.3 Cumberland Pharmaceuticals
13.4 Glaxosmithkline
13.5 Hisamitsu Pharmaceutical
13.6 Lavipharm S.A.
13.7 Luye Pharma Group
13.8 Novartis
13.9 Nutriband
13.10 Pfizer
13.11 UCB
13.12 Viatris

Figure 2-1: Steps Involved in Transdermal Permeation
Figure 2-2: Ideal Properties of Transdermal Patch
Figure 2-3: Types of Commercially Available Transdermal Patch
Figure 2-4: Properties of Transdermal Therapeutics
Figure 2-5: Components of Transdermal Patch
Figure 2-6: Types of Permeation Enhancers
Figure 2-7: Schematic Representation of Iontophoresis
Figure 2-8: Mechanism of Scopolamine Transdermal Patch
Figure 2-9: Mechanism of Nicotine Transdermal Patch
Figure 2-10: Mechanism of Female Contraceptive Transdermal Patch
Figure 3-1: Advantages of Transdermal Patches
Figure 3-2: Disadvantages of Transdermal Patches
Figure 3-3: US - Major Reasons Behind Growth of Transdermal Patches
Figure 3-4: US - Transdermal Patch Market (US$ Billion), 2021 - 2028
Figure 3-5: Potential Market Segments of Transdermal Drug Delivery Systems
Figure 3-6: US - Susceptibility of Parkinson Disease Among Males and Females
Figure 3-7: US - Estimated Increase in Parkinson’s Disease Incidences
Figure 3-8: US - Estimated Financial Impact of Parkinson’s Disease on Economy (US$ Billion)
Figure 3-9: US - Parkinson’s Disease Incidences, 2021-2028
Figure 3-10: US - Estimated Sales of Neupro Patch (US$ Million), 2020-2026
Figure 3-11: US - Male and Female Suffering from Alzheimer’s Disease (Million), 2021
Figure 3-12: US - Shares of Male and Female Suffering from Alzheimer’s Disease (%), 2021
Figure 3-13: US - Percentage of Elderly People Suffering from Alzheimer’s Disease, 2021
Figure 3-14: US - Estimated Increase in Alzheimer’s Incidences (Million), 2020, 2030, 2040 and 2050
Figure 3-15: US - Estimated Incidences of Alzheimer’s Disease (Million), 2021-2028
Figure 3-16: Requirements of Female Contraceptive Transdermal Drug Delivery Systems
Figure 3-17: Benefits of Female Contraceptive Transdermal Drug Delivery System
Figure 3-18: US - Decrease in Number of Smokers due to Nicotine Patch, 2005, 2013 and 2019
Figure 3-19: US - Prevalence of Smokers by Gender (%), 2019
Figure 3-20: Factors Responsible for Increased Consumption of Nicotine Patches
Figure 3-21: US - Estimated Cases of Adult Hypertension (Million), 2019, 2025 and 2030
Figure 3-22: US - Hypertension Incidences (Million), 2021-2028
Figure 3-23: Rank of US among Different Diabetes Prone Countries
Figure 3-24: US - Estimated Diabetic Population (Million), 2019, 2025, 2030 and 2045
Figure 3-25: US - Undiagnosed and Diagnosed Diabetic Population (Million), 2019
Figure 3-26: US - Undiagnosed and Diagnosed Diabetic Population (%), 2019
Figure 3-27: US - Estimated Diabetic Prevalence Rate (%), 2019, 2025, 2030 and 2045
Figure 3-28: US - Estimated Diabetic Population (Million), 2021-2028
Figure 3-29: Benefits of Insulin Transdermal Patch
Figure 3-30: Drawback of Insulin Transdermal Patch
Figure 3-31: Benefits of Vaccine Transdermal Patch
Figure 3-32: Drawbacks of Vaccine Transdermal Patch
Figure 3-33: US - Number of HIV Cases (Million), 2012, 2014 and 2018
Figure 3-34: US - Estimated Number of HIV Cases (Million), 2020, 2025 and 2030
Figure 3-35: US - Estimated HIV Incidences, 2021-2028
Figure 4-1: US - Transdermal Patch Pipeline by Company (Numbers), 2022 till 2028
Figure 4-2: US Transdermal Patch Pipeline by Drug Class (Numbers), 2022 till 2028
Figure 4-3: US Transdermal Patch Pipeline by Indication (Numbers), 2022 till 2028
Figure 4-4: US - Transdermal Patch Pipeline by Phase (%),2021 till 2028
Figure 4-5: US Transdermal Patch Pipeline by Phase (Numbers), 2022 till 2028
Figure 5-1: Catapres-TTS - FDA Approval and First Generic Approval Year
Figure 5-2: Catapres-TTS - Price for 4 Transdermal Film and Price Per Unit of 0.1mg Transdermal Film (US$), September’2022
Figure 5-3: Catapres-TTS - Price for 4 Transdermal Film and Price Per Unit of 0.2mg Transdermal Film (US$), September’2022
Figure 5-4: Catapres-TTS - Price for 4 Transdermal Film and Price Per Unit of 0.3mg Transdermal Film (US$), September’2022
Figure 5-5: Generic Clonidine Patch - Price for 4 Transdermal Film and Price Per Unit of 0.1mg Transdermal Film (US$), September’2022
Figure 5-6: Generic Clonidine Patch - Price for 4 Transdermal Film and Price Per Unit of 0.2mg Transdermal Film (US$), September’2022
Figure 5-7: Generic Clonidine Patch - Price for 4 Transdermal Film and Price Per Unit of 0.3mg Transdermal Film (US$), September’2022
Figure 5-8: Catapres-TTS - Recommended Initial and Incremented Dose (mg/Week)
Figure 5-9: Catapres-TTS - Monthly and Annual Treatment Cost using 0.1mg Dose (US$), September’2022
Figure 5-10: Nitro-Dur - Price for 30 Films Supply and Price Per Unit of 0.1mg Film (US$), September’2022
Figure 5-11: Nitro-Dur - Price for 30 Films Supply and Price Per Unit of 0.2mg Film (US$), September’2022
Figure 5-12: Nitro-Dur - Price for 30 Films Supply and Price Per Unit of 0.3mg Film (US$), September’2022
Figure 5-13: Nitro-Dur - Price for 30 Films Supply and Price Per Unit of 0.4mg Film (US$), September’2022
Figure 5-14: Nitro-Dur - Price for 30 Films Supply and Price Per Unit of 0.6mg Film (US$), September’2022
Figure 5-15: Nitro-Dur - Price for 30 Films Supply and Price Per Unit of 0.8mg Film (US$), September’2022
Figure 5-16: Nitro TD Patch A - Price for 30 Patch supply and Price Per Unit (US$), September’2022
Figure 5-17: Generic Nitroglycerin Transdermal Patch - Price for 30 Films Supply and Price Per Unit of 0.1mg Film (US$), September’2022
Figure 5-18: Generic Nitroglycering Transdermal Patch - Price for 30 Films Supply and Price Per Unit of 0.2mg Film (US$), September’2022
Figure 5-19: Generic Nitroglycering Transdermal Patch - Price for 30 Films Supply and Price Per Unit of 0.4mg Film (US$), September’2022
Figure 5-20: Generic Nitroglycering Transdermal Patch - Price for 30 Films Supply and Price Per Unit of 0.6 mg Film (US$), September’2022
Figure 6-1: Duragesic - FDA Approval Year by Dose
Figure 6-2: Duragesic - First Generic Approval Year by Dose
Figure 6-3: Duragesic - Price for 5 Patch Supply of 12mcg, 25mcg, 50mcg, 75mcg and 100mcg Transdermal Patches (US$), September’2022
Figure 6-4: Duragesic - Price per Unit of 12mcg, 25mcg, 50mcg, 75mcg and 100mcg Transdermal Patches (US$), September’2022
Figure 6-5: Generic Fentanyl Transdermal Patch - Price for 5 Patch Supply of Various Doses (US$), September’2022
Figure 6-6: Generic Fentanyl Transdermal Patch - Price per Unit of Various Doses (US$), September’2022
Figure 6-7: Butrans - FDA Approval Year by Dose
Figure 6-8: Butrans - Price for 4 Patch Supply of 5mcg, 7.5mcg, 10mcg, 15mcg and 20mcg Transdermal Patches (US$), September’2022
Figure 6-9: Butrans - Price per Unit of 5mcg, 7.5mcg, 10mcg, 15mcg and 20mcg Transdermal Patches (US$), September’2022
Figure 6-10: Generic Buprenorphine Transdermal Patch - Price for 4 Patch supply of 5mcg, 7.5mcg, 10mcg, 15mcg and 20mcg Transdermal Patches (US$), September’2022
Figure 7-1: Emsam - Price for 30 Patch Supply and Price Per Unit of Various Doses of Emsam Transdermal Patches (US$), September’2022
Figure 7-2: Emsam - Monthly and Annual Treatment Cost of Parkinson’s Disease (US$), September’2022
Figure 7-3: Transderm-Scop - Price for a Supply of 4, 10 and 24 Patches of 1mg Transdermal Film (US$), September’2022
Figure 7-4: Transderm-Scop - Price for a Supply of 4, 10 and 24 Patches of 1.5mg Transdermal Film (US$), September’2022
Figure 7-5: Generic Scopolamine Transdermal Patch - Price for a Supply of 4, 10 and 24 Patches of 1mg Transdermal Film (US$), September’2022
Figure 7-6: Exelon - Price for 30 Transdermal Patch Supply of Exelon (US$), September’2022
Figure 7-7: Generic Rivastigmine Transdermal Patch - Price for a Supply of 30 Patches of Dose 4.6mg, 9.5mg and 13.3 mg (US$), September’2022
Figure 7-8: Exelon - Initial and Maintenance Dose for the Treatment of Parkinson’s Disease
Figure 7-9: Exelon - Monthly and Annual Treatment Cost for Treatment of Parkinson’s Disease (US$), September’2022
Figure 7-10: Daytrana - Patent Issue and Expiration Year
Figure 7-11: Daytrana - Price for 30 Transdermal Patch Supply of All Doses (US$), September’2022
Figure 7-12: Secuado - Patent Issue and Expiration Year
Figure 7-13: Secuado - Price for 30 Transdermal Film and Price Per Unit of Various Dose Regimens (US$), September’2022
Figure 7-14: Secuado - Recommended Initial and Incremented Dose (mg/Day)
Figure 7-15: US - Aderis Pharma’s Neupro Patent Issue and Expiration Year
Figure 7-16: US - UCB’s Neupro Patent Issue and Expiration Year
Figure 7-17: Neupro - Price for Supply of 30 Transdermal Films and Price Per Unit (US$), September’2022
Figure 7-18: Neupro - Initial and Maximum Recommended Dose for Early Stage Parkinson (mg/day)
Figure 7-19: Neupro - Initial and Maximum Recommended Dose for Advanced Stage Parkinson (mg/day
Figure 7-20: Global - Neupro Sales (US$ Million), 2017-2022*
Figure 7-21: US - Neupro Sales (US$ Million), 2017-2022
Figure 7-22: Global - Neupro Sales by Region (US$ Million), 2021
Figure 7-23: Global - Neupro Sales by Region (US$ Million), 2021
Figure 7-24: Adlarity - Price for 4 Transdermal Patch Supply of All Doses (US$), September’2022
Figure 7-25: Adlarity - Recommended Initial and Incremented Dose (mg/day)
Figure 7-26: Xelstrym - Recommended Initial, Incremented and Maximum Doses (mg/day)
Figure 8-1: Vivelle-Dot - FDA Approval and First Generic Approval Year
Figure 8-2: Vivelle-Dot - Price for a Supply of 8 Patches of Dose 0.025mg, 0.0375mg, 0.05mg, 0.075mg and 0.1mg (US$), September’2022
Figure 8-3: Vivelle-Dot - Price per Unit of 0.025mg, 0.0375mg, 0.05mg, 0.075mg and 0.1mg Transdermal Patch (US$), September’2022
Figure 8-4: Recommended Dose for Treatment of vaginal Atrophy, vasomotor Symptoms, and Postmenopausal Osteoporosis (mg/Day Twice a Week)
Figure 8-5: Minivelle - FDA Approval Year by Dose
Figure 8-6: Minivelle - FDA Approval and First Generic Approval Year
Figure 8-7: US - Minivelle Patent Issue and Expiration Year
Figure 8-8: Minnivelle - Price for a Supply of 8 Patches and Price Per Unit of Various Doses (US$), September’2022
Figure 8-9: Minivelle - Recommended Dose by Indication (mg/Day)
Figure 8-10: Climara - FDA Approval Year by Dose
Figure 8-11: Climara - FDA Approval and First Generic Approval Year
Figure 8-12: Climara - Average Price for a Supply of 4 Transdermal Films and Price Per Unit of Various Doses (US$), March’2021
Figure 8-13: Menostar - Price for a Supply of 4 Patches of Dose 14 mcg (US$), September’2022
Figure 8-14: Generic Estradiol Transdermal Patch - Price Per 4 and 8 Films Supply and Price Per Unit of 0.025mg Film (US$), September’2022
Figure 8-15: Generic Estradiol Transdermal Patch - Price for 4 and 8 Films Supply and Price Per Unit of 0.0375mg Film (US$), September’2022
Figure 8-16: Generic Estradiol Transdermal Patch - Price for 4 and 8 Films Supply and Price Per Unit of 0.05mg Film (US$), September’2022
Figure 8-17: Generic Estradiol Transdermal Patch - Price for 4 Supply and Price Per Unit of 0.06mg Film (US$), September’2022
Figure 8-18: Generic Estradiol Transdermal Patch - Price for 4 and 8 Films Supply and Price Per Unit of 0.075mg Film (US$), September’2022
Figure 8-19: Generic Estradiol Transdermal Patch - Price for 4 and 8 Films Supply and Price Per Unit of 0.1mg Film (US$), September’2022
Figure 8-20: Androderm - Price for 60 Films Supply and per Unit Price of 2mg Transdermal Films (US$), September’2022
Figure 8-21: Androderm - Price for 30 patch Supply and per Unit Price of 4mg Transdermal Patch (US$), September’2022
Figure 8-22: Androderm - Recommended Initial and Maintainence Dose fot Treatment of Hypogonadism (mg/day)
Figure 8-23: Ortho Evara - FDA approval and Withdrawal Year
Figure 8-24: Xulane - FDA Approval and First Generic Approval Year
Figure 8-25: Xulane - Price for a Supply of 3 Patches and Price Per Unit of 35mcg-150mcg Transdermal Patch (US$), September’2022
Figure 8-26: Xulane - Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 8-27: CombiPatch - Price for a Supply of 8 Patches and Price Per Unit of Various Doses (US$), September’2022
Figure 8-28: Climara Pro - Price for a Supply of 4 Films and Price Per Unit of Transdermal Film (US$), September’2022
Figure 8-29: US - Twirla Patent Issue and Expiration Year
Figure 8-30: Twirla - Price for a Supply of 3 Patches and Price Per Unit of 30mcg-120mcg Transdermal Patch (US$), September’2022
Figure 8-31: Twirla - Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 9-1: Nicotine Transdermal Patch - FDA Approval Year by Product
Figure 9-2: Nicoderm CQ - Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg and 21mg (US$), September’2022
Figure 9-3: Nicoderm CQ - Price per Unit of 7mg, 14mg and 21mg Transdermal Patch (US$), September’2022
Figure 9-4: Harbitrol - Price for a Supply of 28 Transdermal Patches of Doses 7mg, 14mg and 21mg (US$), March’2021
Figure 9-5: Generic Nicotine Patch - Price for a Supply of 7 Transdermal Patches of Doses 7mg, 14mg and 21mg (US$), September’2022
Figure 9-6: Generic Nicotine Patch - Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg and 21mg (US$), September’2022
Figure 9-7: Generic Nicotine Patch - Price for a Supply of 28 Transdermal Patches of Doses 14mg and 21mg (US$), September’2022
Figure 9-8: Nicoderm CQ - Recommended Dose and Treatment Schedule for Patients with Consumption More Than 10 Cigarette/Days (mg/day)
Figure 9-9: Nicoderm CQ - Recommended Dose and Treatment Schedule for Patients with Consumption of Less Than 10 Cigarette/Days (mg/day)
Figure 9-10: Nicoderm CQ - Full Treatment Cost for Patient with Daily Consumption of Less than 10 Cigarettes and More than 10 Cigarettes (US$), March’2021
Figure 9-11: Oxytrol - Price of 8 Patch Supply and Price Per Unit of 3.9mg Transdermal Patch (US$), September’2022
Figure 9-12: Oxytrol For Women - Price of 4 Patch Supply and Price Per Unit of 3.9mg Transdermal Patch (US$), September’2022
Figure 9-13: Oxytrol For Women - Price of 8 Patch Supply and Price Per Unit of 3.9mg Transdermal Patch (US$), September’2022
Figure 9-14: Sancuso - Patent Issue and Expiration Year
Figure 12-1: Transdermal Patch Market Favorable Factors
Figure 12-2: Transdermal Patch Market Commercialization Challenges

Table 2-1: Differences between Active and Passive Transdermal Patches
Table 2-2: Transdermal Patches for Various Disease Indications
Table 3-1: Features Required in Transdermal Patches
Table 3-2: US - Different Transdermal Drug Delivery Systems Available in Market
Table 3-3: US - Estimated Adoption Rates for Parkinson's Disease Transdermal Patches, 2021-2028
Table 3-4: Description of Neupro Patch for Parkinson’s Disease
Table 3-5: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer's Disease, 2021-2028
Table 3-6: Transdermal Patches for Alzheimer’s Disease
Table 3-7: Description of Ortho Evra Contraceptive Patch
Table 3-8: Difference Between Generic and Branded Transdermal Contraceptive Products
Table 3-9: US - Estimated Adoption Rates for Nicotine Transdermal Patches, 2022-2028
Table 3-10: Clonidine Patch - Difference Between Generic and Branded Transdermal Patch
Table 3-11: US - Estimated Adoption Rates for Hypertension Transdermal Patches, 2021-2028
Table 3-12: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2021-2028
Table 3-13: US - Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2021-2028
Table 6-1: Duragesic - Initial Dose Conversion from Other Opioids
Table 6-2: Butrans - Initial Dose Calculation using Previous Opioid (Morphine) Dosage
Table 7-1: Daytrana - Dose Increment Pattern for Treatment of ADHD